×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Mersana Therapeutics to Present at Upcoming Investor Conferences
Yahoo Finance
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company...
3 days ago
It's a wrap for Merck KGaA and Mersana's 2014 ADC pact
Fierce Biotech
Mersana Therapeutics and Merck KGaA have severed ties for a licensing pact related to one of Mersana's ADC platforms.
5 months ago
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
GlobeNewswire
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company...
3 weeks ago
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Simply Wall Street
The Final Word. Mersana Therapeutics' recently weak share price has pulled its P/S back below other Biotechs companies. Generally, our...
1 month ago
Foundations Investment Advisors LLC Acquires New Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN)
Defense World
Read Foundations Investment Advisors LLC Acquires New Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) at Defense World.
5 days ago
FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death
BioSpace
The regulator has released Mersana Therapeutics' antibody-drug conjugate XMT-2056 from its clinical hold, allowing the biotech to proceed...
6 months ago
Form 424B5 Mersana Therapeutics,
StreetInsider
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271766. PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2024). $100,000,000.
2 weeks ago
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts...
2 weeks ago
Mersana halves workforce as shares plummet 75% in wake of lead cancer drug's failure
Fierce Biotech
The failure of Mersana Therapeutics' lead ovarian cancer drug in a phase 1/2 trial has sent the biotech into a tailspin, resulting in...
9 months ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company...
3 weeks ago